Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Specific subsets of mesenchymal stroma cells to treat lung disorders - Finding the Holy Grail.

Rolandsson Enes, Sara LU orcid ; Karlsson, Jenny C LU ; Scheding, Stefan LU and Westergren-Thorsson, Gunilla LU orcid (2014) In Pulmonary Pharmacology & Therapeutics 29(2). p.93-95
Abstract
Accumulating studies, both in animals and human clinical trials with mesenchymal stroma cells (MSC) support the hypothesis of therapeutic effects of these cells in various disorders. However, despite success in immune-mediated disorders such as Crohns' disease, lung disorders such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary disease (IPF) treated with MSC have so far not yielded a revolutionary effect on clinical symptoms. Promising data on immunomodulatory effects in COPD have kept nourishing the research into finding specific traits of MSC beneficial in disease. A heterogeneous population of injected cells might drown a potential therapeutic role of a specific group of MSC. Thus careful analysis of MSC... (More)
Accumulating studies, both in animals and human clinical trials with mesenchymal stroma cells (MSC) support the hypothesis of therapeutic effects of these cells in various disorders. However, despite success in immune-mediated disorders such as Crohns' disease, lung disorders such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary disease (IPF) treated with MSC have so far not yielded a revolutionary effect on clinical symptoms. Promising data on immunomodulatory effects in COPD have kept nourishing the research into finding specific traits of MSC beneficial in disease. A heterogeneous population of injected cells might drown a potential therapeutic role of a specific group of MSC. Thus careful analysis of MSC regarding their molecular capabilities such as delivering specific therapeutic vesicles to the environment, or plain cytokine/chemokine fingerprinting might prove useful in augmenting therapies against lung diseases. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Pulmonary Pharmacology & Therapeutics
volume
29
issue
2
pages
93 - 95
publisher
Elsevier
external identifiers
  • pmid:25239767
  • wos:000345949900002
  • scopus:84922584613
ISSN
1522-9629
DOI
10.1016/j.pupt.2014.08.001
language
English
LU publication?
yes
id
aee9bf77-0f11-4aaf-aa9c-3eb16c3331de (old id 4691180)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25239767?dopt=Abstract
date added to LUP
2016-04-01 11:14:20
date last changed
2024-01-07 11:01:00
@article{aee9bf77-0f11-4aaf-aa9c-3eb16c3331de,
  abstract     = {{Accumulating studies, both in animals and human clinical trials with mesenchymal stroma cells (MSC) support the hypothesis of therapeutic effects of these cells in various disorders. However, despite success in immune-mediated disorders such as Crohns' disease, lung disorders such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary disease (IPF) treated with MSC have so far not yielded a revolutionary effect on clinical symptoms. Promising data on immunomodulatory effects in COPD have kept nourishing the research into finding specific traits of MSC beneficial in disease. A heterogeneous population of injected cells might drown a potential therapeutic role of a specific group of MSC. Thus careful analysis of MSC regarding their molecular capabilities such as delivering specific therapeutic vesicles to the environment, or plain cytokine/chemokine fingerprinting might prove useful in augmenting therapies against lung diseases.}},
  author       = {{Rolandsson Enes, Sara and Karlsson, Jenny C and Scheding, Stefan and Westergren-Thorsson, Gunilla}},
  issn         = {{1522-9629}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{93--95}},
  publisher    = {{Elsevier}},
  series       = {{Pulmonary Pharmacology & Therapeutics}},
  title        = {{Specific subsets of mesenchymal stroma cells to treat lung disorders - Finding the Holy Grail.}},
  url          = {{https://lup.lub.lu.se/search/files/2497739/5310410}},
  doi          = {{10.1016/j.pupt.2014.08.001}},
  volume       = {{29}},
  year         = {{2014}},
}